Company profile: IRLAB Therapeutics
1.1 - Company Overview
Company description
- Provider of drug discovery and development for brain disorders, targeting core dysfunctions in Parkinson’s disease and dementias. Offers ISP, a proprietary systems pharmacology platform built on a unique CNS compound database, and is advancing two phase II candidates: Mesdopetam (IRL790) for levodopa-induced dyskinesia and Pirepemat (IRL752) for impaired balance and reducing falls in Parkinson’s disease.
Products and services
- Mesdopetam (IRL790): A phase-II drug candidate targeting levodopa-induced dyskinesia in Parkinson’s disease, engineered to offer improved clinical benefit
- Pirepemat (IRL752): A phase-II drug candidate for Parkinson’s disease, developed to treat impaired balance and reduce falls, intended to deliver improved clinical benefit
- ISP: A proprietary technology platform for drug discovery in brain disorders, leveraging a systems pharmacology approach and a unique database of CNS compounds to identify novel treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IRLAB Therapeutics
Mission Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule therapeutics targeting deubiquitylating enzymes to enhance mitophagy and remove dysfunctional mitochondria for the treatment of cancer, acute kidney injury, and other diseases. Offerings include MTX325 (CNS-penetrant USP30 inhibitor), MTX652 (peripheral USP30 inhibitor), a proprietary DUB platform, and USP30 inhibitor programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mission Therapeutics company profile →
Trevena
HQ: United States
Website
- Description: Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevena company profile →
Supernus Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinson’s disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Supernus Pharmaceuticals company profile →
Phagenesis
HQ: United Kingdom
Website
- Description: Provider of neurostimulation solutions for dysphagia treatment, developing the Phagenyx System, which delivers Pharyngeal Electrical Stimulation to restore neurological control of swallowing. The system tailors stimulation to patient sensory capacity and uses a dual-function catheter for feeding and electrical therapy, harnessing neuroplasticity to improve safe swallowing in patients, including those post-stroke or with neuro-deficit diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phagenesis company profile →
AxoGen
HQ: United States
Website
- Description: Provider of treatment options for peripheral nerve reconstruction and repair, offering Avance® Nerve Graft to bridge nerve discontinuities and facilitate regeneration, Axoguard Nerve Cap® to protect and isolate nerve ends to reduce neuroma formation, Axoguard® Nerve Connector for tensionless coaptation, and Axoguard® Nerve Protector to prevent soft tissue attachments and support nerve healing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AxoGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IRLAB Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IRLAB Therapeutics
2.2 - Growth funds investing in similar companies to IRLAB Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IRLAB Therapeutics
4.2 - Public trading comparable groups for IRLAB Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →